BOLT
NASDAQBolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc. (BOLT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for BOLT, including 2 SEC filings, 2 insider trades and 1 earnings update. The most recent was published Nov 3, 2026.
BOLT rankings
Financial highlights
Full financials- Revenue, TTM
- $4.70M
- Revenue growth
- +12.8%
- Net income, TTM
- -$28.74M
- Net margin
- -611.5%
- Cash
- $12.86M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks17+25%
2026-05-102026-11-01
Mix1390d
- Insider5(38%)
- SEC Filings4(31%)
- Other3(23%)
- Earnings1(8%)
Latest news
25 items- PRBolt Biotherapeutics to Participate in Upcoming ConferencesREDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) ("Bolt" or the "Company"), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced participation in two upcoming investor conferences. Sheila Gujrathi, M.D., Chief Strategy Officer of Bolt and Co-Founder and former Chief Executive Officer of Prana Therapies, will deliver a company presentation, followed by a fireside chat, on Tuesday, November 10, 2026, at 10:40 a.m. ET at the Stifel 2026 Healthcare Conference, and attend Jefferies Global Healthcare Conference in London, taki
- INSIDERSEC Form 4 filed by Bolt Biotherapeutics Inc.4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 3 filed by Bolt Biotherapeutics Inc.3 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- SECSEC Form 8-K filed by Bolt Biotherapeutics Inc.8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- PRBolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory IndicationsTransactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platformPRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, with a Phase 2 study in EoE planned; patient data from all four trials expected beginning in the second quarter of 2027Concurrent private placement of $120 million in upfront financing with the potential to receive up to an additional $60 million upon exercise of accompanying warrants secured from leading healthcare institutional investors is expected to fund operations into 2028Following the transactio
- SECSEC Form 8-K filed by Bolt Biotherapeutics Inc.8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- INSIDERPresident, CEO and CFO Quinn William P. bought $2,469 worth of shares (637 units at $3.88) and sold $58,402 worth of shares (17,566 units at $3.32), increasing direct ownership by 997% to 25,384 units (SEC Form 4) to satisfy withholding tax4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSenior VP, Finance and PAO Nemec Sarah bought $1,973 worth of shares (509 units at $3.88) and sold $26,072 worth of shares (7,842 units at $3.32), increasing direct ownership by 1,107% to 17,082 units (SEC Form 4) to satisfy withholding tax4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERChief Operating Officer Yonehiro Grant sold $43,807 worth of shares (13,176 units at $3.32), decreasing direct ownership by 43% to 17,269 units (SEC Form 4) to satisfy tax liability4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Bolt Biotherapeutics Inc.SCHEDULE 13G - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
- SECSEC Form 10-Q filed by Bolt Biotherapeutics Inc.10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECBolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- PRBolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateFirst-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 resultsCash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. "In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and ga
- ANALYSTRodman & Renshaw initiated coverage on Bolt Biotherapeutics with a new price targetRodman & Renshaw initiated coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $22.00
- SECSEC Form 10-Q filed by Bolt Biotherapeutics Inc.10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECBolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- PRBolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateFirst-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. "We are encouraged by what we have seen thus far in patients treated with BDC
- SECSEC Form DEFA14A filed by Bolt Biotherapeutics Inc.DEFA14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECSEC Form DEF 14A filed by Bolt Biotherapeutics Inc.DEF 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECSEC Form S-8 filed by Bolt Biotherapeutics Inc.S-8 - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECSEC Form 10-K filed by Bolt Biotherapeutics Inc.10-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECBolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- PRBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateFirst-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. "BDC-4182 is the first of our next-generation Boltbody™ ISACs to enter the clinic, and we saw a clear difference versus our first-gen
- PRBolt Biotherapeutics to Participate in Upcoming March ConferencesREDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 46th Annual Health Care ConferenceCompany presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST)Leerink Partners Global Healthcare ConferenceParticipating in 1x1 meetings on Wednesday, March 11, 2026 About Bolt Biotherapeutics, Inc.The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182,
- INSIDERPresident, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
BOLT FAQ
11 questionsWhat does Bolt Biotherapeutics Inc. do?
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators...What is the latest news on BOLT?
In the last 30 days Quantisnow tracked 6 wire items for BOLT: 2 SEC filings, 2 insider trades, 1 earnings update and 1 press release or news item. The most recent was published on November 3, 2026.What is BOLT revenue?
Bolt Biotherapeutics Inc. (BOLT) reported $4.70M of revenue for the twelve months ended Jun 30, 2026. That is up 12.8% from the year before. Revenue for fiscal 2025 was $7.70M.Is BOLT profitable?
No. Bolt Biotherapeutics Inc. reported a net loss of $28.74M for the twelve months ended Jun 30, 2026.How much cash and debt does BOLT have?
Bolt Biotherapeutics Inc. reported $12.86M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does BOLT stock trade?
Bolt Biotherapeutics Inc. (BOLT) is listed on NASDAQ.What sector and industry is BOLT in?
Bolt Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Bolt Biotherapeutics Inc. go public?
Bolt Biotherapeutics Inc. (BOLT) completed its IPO in 2021.What are analysts saying about BOLT?
Across the last 6 analyst actions on Bolt Biotherapeutics Inc., there were 0 upgrades and 2 downgrades. The most recent action was from Rodman & Renshaw: Buy with a $22.00 price target on 2026-05-29. Recent price targets range from $7.00 to $35.00.What companies are similar to BOLT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BOLT side-by-side with any of them on Quantisnow.How can I track BOLT on Quantisnow?
Quantisnow aggregates Bolt Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BOLT to receive live email and push alerts on every new disclosure.